Roche Will Use REMS Program Data To Show Actemra Is Safe For First-Line RA
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss pharma's Genentech unit announced tocilizumab approval for failed TNF patients Jan. 8, saying it is committed to seek earlier uses with post-marketing data, including data from pharmacovigilance and risk plans as well as clinical studies.